Government-subsidised access to effective medicines in Australia is provided via the Pharmaceutical Benefits Scheme (PBS). Decisions to subsidise medicines are based on assessment of cost-effectiveness (“value for money”) by the Pharmaceutical Benefits Advisory Committee (PBAC).1 In effect, the PBS is “purchasing” health outcomes. As the majority of medicine use is publicly funded via the PBS, there is an obligation to monitor the outcomes to determine whether the expected health improvements are actually realised.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Sansom L. The subsidy of pharmaceuticals in Australia: processes and challenges. Aust Health Rev 2004; 28: 194-205.
- 2. The National Strategy for Quality Use of Medicines: executive summary. Canberra: Australian Government Department of Health and Ageing, 2002.
- 3. Portfolio budget statement 2005–06: Federal Health Budget 2005–06. Canberra: Australian Department of Health and Ageing, 2005.
- 4. Lu CY, Williams KM, Day RO, et al. Access to high cost drugs in Australia: risk sharing scheme may set a new paradigm. BMJ 2004; 329: 415-416.
- 5. Lu CY, Williams KM, Day RO. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target? Intern Med J 2006; 36: 19-27.
- 6. Lu CY, Williams KM, Day RO. Evaluation of access to high-cost medicines in Australia using national claims data [abstract]. Value in Health 2005; 8: A28.
- 7. Australian Government Health Insurance Commission. 2003–04 Annual report. Canberra: HIC, 2004.
- 8. Robertson J, Fryer JL, O’Connell DL, et al. Limitations of Health Insurance Commission (HIC) data for deriving prescribing indicators. Med J Aust 2002; 176: 419-424. <MJA full text>
- 9. Australian Government. Office of the Privacy Commissioner. 2004 Review of the Medicare and PBS Privacy Guidelines issued under section 135AA of the National Health Act 1953. Canberra: Office of the Privacy Commissioner, 2004. Available at: http://www.privacy.gov.au/health/guidelines/healthreview.html (accessed Mar 2006).
Kenneth Williams has been a member of the Advisory Board to the sponsor for adalimumab. Richard Day is a member of the Advisory Board to sponsors for adalimumab, infliximab, and anakinra in Australia. Kenneth Williams and Richard Day have also been contracted to undertake clinical trials of etanercept, infliximab, adalimumab, and anakinra. Recompense for these activities was placed in audited hospital trust funds for use in the research activities of the Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, NSW.